Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan, October 28, 2011 – The Astellas Asia-Oceania Foundation announced that it will make a donation of USD $20,000 to the Thai Red Cross Society to assist with relief efforts after the...
Tokyo, Japan, October 17, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced that the Societe Internationale d’Urologie (SIU) presented its senior science advisor (and former...
Tokyo, September 28, 2011 -Astellas Pharma Inc. (Tokyo:4503, “Astellas”) announced that it has decided to discontinue the global development of darexaban maleate (generic name, development...
Astellas Pharma Inc. (Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka) today announced that the administration of the seasonal influenza HA vaccine ASP7374 (former code: UMN-0502) was...
Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo;...
Tokyo, Japan, September 7, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced the donation of three high-standard ambulances to local municipalities in Japan. The numbers of calls...
Tokyo & Sapporo, Japan, September 5, 2011 – Evec, Inc. (”Evec”) and Astellas Pharma Inc. (Tokyo:4503, “Astellas”) today announced that they have entered into a license agreement for one...
Tokyo, August 30, 2011 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced that it has decided to sell the fixed asset listed below. 1． Details of Fixed Asset to Be Sold Asset:...
Teijin Pharma Limited and Astellas Pharma Inc. announced that they have entered into an exclusive distribution agreement for febuxostat (generic name, development code: TMX-67), a novel drug for...
Tokyo, July 28, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) announced today that it was granted approval for the additional indication...
Tokyo, July 22, 2011 – Astellas Pharma Inc. (“Astellas,” Tokyo: 4503) today announced that it will once again hold the “Changing Tomorrow Day” (CT Day) this year as part of its global...
Tokyo, July 14, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) announced today that Astellas and its Canadian affiliate Astellas Pharma...
Follow us
